Company Overview and News
In the value stocks versus growth stocks tug-of-war, growth stocks have been the unequivocal winner for the past several years. But that may change soon.
SIG TIF TWX SKX WMT KR AMZN NKE AAPL DKS KSS KITE INTC DIS GE GEC AMC GILD M TWC FOSL SIG TGT T MU ZUMZ GNE GPS NTAP FL
LYNNWOOD, Wash., June 08, 2018 (GLOBE NEWSWIRE) -- Zumiez Inc. (NASDAQ:ZUMZ) a leading specialty retailer of apparel, footwear, equipment and accessories for young men and women, today announced that management will present at the William Blair 38th Annual Growth Stock Conference in Chicago, IL. The presentation is scheduled for Tuesday, June 12, 2018 at 10:10 am Central Time. The live webcast can be accessed via the investor relations page of Zumiez website at http://ir.
Chicago, IL – June 8, 2018 – Zacks Equity Research highlights Micron Technology (MU - Free Report) as the Bull of the Day, L Brands (LB - Free Report) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Zumiez Inc. .
UFPI BKNG TTWO MU FIX PATK ZUMZ LB PETS
Good afternoon, ladies and gentlemen, and welcome to the Zumiez Inc. First Quarter Fiscal 2018 Earnings Conference Call. At this time, all participants are in a listen-only mode. We will conduct a question-and-answer session towards the end of this conference.
Zumiez Inc. just released its first-quarter financial results, posting an adjusted loss of $0.10 per share and revenues of $206.29 million.
COF.PRG COF.PRH COF-P COF.WS COF.PRP COF SFIX COF-D COF-C COF-F ZUMZ COF.PRC OXY COF.PRD COF.PRF
LYNNWOOD, Wash., June 07, 2018 (GLOBE NEWSWIRE) -- Zumiez Inc. (NASDAQ:ZUMZ) a leading specialty retailer of apparel, footwear, equipment and accessories for young men and women, today reported results for the first quarter ended May 5, 2018.
Here’s a surprise headline that you probably thought you’d never read again: retail stocks are in rally mode. And they have been for several months now. Since early November, the SPDR S&P Retail (ETF) (NYSEARCA:XRT) is up 18%, versus a mere 5% gain for the S&P 500. Within that exchange-traded funds, many of the big names in retail have staged 50%-plus rallies.
RL ANF M JWN AMZN KORS EXPR LULU AEO DKS ZUMZ KSS FL URBN
With the current headlines, you might wonder what would even be on a list of the best May stocks. But, believe it or not, despite rising geopolitical and inflationary risks, the market is on track to have its best May in several years.
JD FB TIF BZUN TCEHY TLYS M NFLX MOMO GOOG NVDA BABA TJX AMZN GOOGL AAPL ZUMZ AEO KSS TCTZF FL URBN BIDU
I suggest a simple approach of finding the best and worst companies in the fashion and retail sector, based on straightforward scoring system using fundamental criteria and accounting data.
SMRT GOOS WWW TLYS LE UAA BOSSY 514414 PLCE ROST LUX OXM JILL UA ZUMZ AEO CBK HUGPF OXFORDIN CHS TTM
PriceSmart, Inc. (PSMT - Free Report) has been witnessing robust sales performance for a while now despite an evolving retail landscape. The company’s net sales rose 1.6% year over year to $240.3 million for April, following increase of 8.9%, 6.6% and 6.2% in March, February and January, respectively. Also, comparable warehouse club sales rose 1.9% for the four weeks (ended Apr 29, 2018). Comps grew 3.
PSMT ZUMZ COST LB
2018-06-22 - Asif
Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...
2018-06-22 - Asif
Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
as of ET